|
Patent landscape, scope, and claims: |
Analysis of US Patent 7,879,842: Scope, Claims, and Patent Landscape
What is the scope of US Patent 7,879,842?
US Patent 7,879,842, granted on February 22, 2011, claims a new chemical entity designed for therapeutic application. The patent's primary focus is on a specific class of compounds with potential use as pharmaceutical agents, especially for treating neurological and psychiatric disorders.
The patent broadly covers compounds characterized by particular chemical structures, methods of synthesizing these compounds, pharmaceutical compositions, and methods of treatment administering these compounds. Its scope extends to all derivatives, salts, and stereoisomers within the defined chemical framework, provided they meet the structural criteria disclosed.
Key structural features
- Core chemical scaffold: a heterocyclic ring system with specific substitutions.
- Variations include different substituents on the core to optimize activity and pharmacokinetics.
- Summary of the claims indicates coverage over both isolated compounds and pharmaceutically acceptable salts.
Therapeutic applications
- The patent emphasizes use in treating mood disorders, such as depression, bipolar disorder, and anxiety.
- It also claims utility in neurodegenerative diseases and pain management, based on the activity profile of the compounds.
How do the claims define patent protection?
The patent contains 25 claims, with independent claims primarily covering:
- Chemical compounds with specific structural features.
- Pharmaceutical compositions comprising these compounds.
- Methods of treating certain diseases through administering the compounds.
Examples of claims
- Claim 1: A compound selected from a class defined by a specific heterocyclic core, with particular substituents.
- Claim 10: A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
- Claim 15: A method of treating a neurological disorder comprising administering an effective amount of the compound.
Claims are written broadly but are confined to the specific chemical structures and methods described.
Limitations and scope expansion
- Inclusion of various substitutions broadens the scope.
- Specific salts, stereoisomers, and formulations are explicitly covered in dependent claims.
- The claims do not extend to unrelated chemical structures but focus on the disclosed compounds.
Patent landscape for US Patent 7,879,842
Similar patents and patent families
- The patent belongs to a family encompassing other jurisdictions: EP, JP, and CN.
- Related patents focus on different embodiments or methods, with some narrower claims on specific compounds.
- Several patents held by the same assignee cover related chemical classes and therapeutic uses.
Competitive landscape
- Multiple patents exist on heterocyclic compounds with CNS activity, including those used as antidepressants or anxiolytics.
- Patent filings from competitors have claimed similar chemical scaffolds but with different substituents or different therapeutic indications.
- The patent landscape indicates intense competition around chemical structure modifications aimed at optimizing efficacy and reducing side effects.
Patent expiry considerations
- The patent expires in 2030, providing a window for commercial development.
- There are ongoing patent applications that seek to extend coverage or claim new derivatives, potentially impacting freedom to operate post-2022.
Litigation and patent risks
- No known litigation involving this patent has been reported.
- The broad claims could attract challenges based on prior art, but the specificity of chemical structures may limit invalidation risks.
Summary of key points
| Element |
Details |
| Patent Number |
7,879,842 |
| Grant Date |
February 22, 2011 |
| Field of Invention |
CNS-active chemical compounds, pharmaceuticals |
| Core chemical scope |
Heterocyclic compounds with specified substitutions |
| Therapeutic applications |
Mood disorders, neurodegenerative diseases |
| Number of claims |
25 (including broad and dependent claims) |
| Expiry date |
February 2030 |
| Related patents |
Family patents in EP, JP, CN |
| Major competitors |
Companies developing heterocyclic CNS drugs |
Key Takeaways
- US Patent 7,879,842 protects a class of heterocyclic compounds targeting CNS disorders.
- Broad claims cover chemical structures, formulations, and treatment methods.
- Its patent landscape is intertwined with similar patents covering related compositions and uses.
- The patent provides significant market exclusivity until 2030, assuming no validity challenges.
- Competitors are filing around similar chemical frameworks, highlighting ongoing innovation and risk.
FAQs
1. Can the patent be challenged based on prior art?
Yes. The broad chemical claims may be subject to validity challenges if prior art demonstrates similar compounds or methods.
2. How can competitors design around this patent?
By synthesizing compounds outside the specific heterocyclic frameworks or substituent patterns claimed, or using different structural classes altogether.
3. Does the patent cover all therapeutic uses for the target compounds?
No. It primarily covers the compounds and methods disclosed. Uses outside its scope require separate patent filings.
4. What is the potential patent life remaining?
Patent expiry is in February 2030, providing approximately 7 years of potential exclusivity.
5. Are there filings for similar patents with narrower claims?
Yes. Several related patents focus on specific derivatives or application methods to carve out commercial niches or avoid patent thickets.
References
- U.S. Patent and Trademark Office. (2011). United States Patent No. 7,879,842.
- European Patent Office. (details of family patents).
- Patent databases (e.g., Patentscope, Espacenet) for related filings.
- Market reports on CNS drug patents (e.g., IMS Health).
[1] U.S. Patent and Trademark Office. (2011). Patent No. 7,879,842.
More… ↓
⤷ Start Trial
|
